Beijing Hotgen Biotech Co. Ltd. Class ASSE: 688068

"BEIJING HOTGEN BIOTECH CO., LTD."Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 Injection

· Issued by Beijing Hotgen Biotech Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining "Drug Clinical Trial Approval" for New Indication of Subsidiary's Innovative Drug SGC001 Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Beijing Hotgen Biotech Co. Ltd. Class A

All Beijing Hotgen Biotech Co. Ltd. Class A news releases